PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY INDICATION
• Market segmentation by indication
• Comparison by indication
• Pulmonary embolism – Market size and forecast 2018-2023
• DVT – Market size and forecast 2018-2023
• Market opportunity by indication
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Boehringer Ingelheim
• Bristol-Myers Squibb
• DAIICHI SANKYO
• Johnson & Johnson
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Years in consideration
Exhibit 02: Global hematology drugs market
Exhibit 03: Segments of global hematology drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Global thrombosis drugs market pipeline: Overview
Exhibit 19: Indication – Market share 2018-2023 (%)
Exhibit 20: Comparison by indication
Exhibit 21: Pulmonary embolism – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Pulmonary embolism – Year-over-year growth 2019-2023 (%)
Exhibit 23: DVT – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: DVT – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by indication
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 33: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Decision framework
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Boehringer Ingelheim – Vendor overview
Exhibit 45: Boehringer Ingelheim – Business segments
Exhibit 46: Boehringer Ingelheim – Organizational developments
Exhibit 47: Boehringer Ingelheim – Geographic focus
Exhibit 48: Boehringer Ingelheim – Segment focus
Exhibit 49: Boehringer Ingelheim – Key offerings
Exhibit 50: Boehringer Ingelheim – Key customers
Exhibit 51: Bristol-Myers Squibb – Vendor overview
Exhibit 52: Bristol-Myers Squibb – Business segments
Exhibit 53: Bristol-Myers Squibb – Organizational developments
Exhibit 54: Bristol-Myers Squibb – Geographic focus
Exhibit 55: Bristol-Myers Squibb – Key offerings
Exhibit 56: Bristol-Myers Squibb – Key customers
Exhibit 57: DAIICHI SANKYO – Vendor overview
Exhibit 58: DAIICHI SANKYO – Business segments
Exhibit 59: DAIICHI SANKYO – Organizational developments
Exhibit 60: DAIICHI SANKYO – Geographic focus
Exhibit 61: DAIICHI SANKYO – Key offerings
Exhibit 62: DAIICHI SANKYO – Key customers
Exhibit 63: Johnson & Johnson – Vendor overview
Exhibit 64: Johnson & Johnson – Business segments
Exhibit 65: Johnson & Johnson – Organizational developments
Exhibit 66: Johnson & Johnson – Geographic focus
Exhibit 67: Johnson & Johnson – Segment focus
Exhibit 68: Johnson & Johnson – Key offerings
Exhibit 69: Johnson & Johnson – Key customers
Exhibit 70: Sanofi – Vendor overview
Exhibit 71: Sanofi – Business segments
Exhibit 72: Sanofi – Organizational developments
Exhibit 73: Sanofi – Geographic focus
Exhibit 74: Sanofi – Segment focus
Exhibit 75: Sanofi – Key offerings
Exhibit 76: Sanofi – Key customers
Exhibit 77: Validation techniques employed for market sizing
Exhibit 78: List of abbreviations
【掲載企業】
Boehringer Ingelheim、Bristol-Myers Squibb、DAIICHI SANKYO、Johnson & Johnson、Sanofi